Illumina Gets FDA Approval for Cancer Biomarker Test

Illumina received Food and Drug Administration approval for its TruSight Oncology Comprehensive biomarker test for cancer and its two companion diagnostic uses.

The biotechnology company said Tuesday that the test checks more than 500 genes to profile solid tumors, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers for targeted therapy options or clinical trial enrollment.